Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

WILLIAMS AND JENSEN, PLLC filed a Q3 report for AMGEN, INC. on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for AMGEN, INC. · An American multinational biopharmaceutical company

All filings by WILLIAMS AND JENSEN, PLLC · Everything AMGEN, INC. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 2
  • CHRISTOPHER E. WILCOX
    Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
  • JEANNE HAGGERTY
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Medicare/Medicaid

Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars.

Taxation/Internal Revenue Code

Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.

Budget/Appropriations

Policies impacting disease prevention.

Labor Issues/Antitrust/Workplace

Issues related to antitrust legislation.

Copyright/Patent/Trademark

Issues related to patent protections.

Health Issues

General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals.

 Bills named in this filing 1
  • H.R. 1
    One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem